Research programme: osteoporosis therapeutics - Metabolic Pharmaceuticals/University of Auckland

Drug Profile

Research programme: osteoporosis therapeutics - Metabolic Pharmaceuticals/University of Auckland

Alternative Names: Adn 27-52; Am 1-8; MBP 0250; MBP 0260

Latest Information Update: 11 May 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator University of Auckland
  • Developer Metabolic Pharmaceuticals; University of Auckland
  • Class
  • Mechanism of Action Osteogenesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Osteoporosis

Most Recent Events

  • 31 Aug 2002 Preclinical trials in Osteoporosis in Australia (SC)
  • 31 Aug 2002 Preclinical trials in Osteoporosis in New Zealand (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top